Immunoexpression of CD44, p16 and VEGF in oral cancer.

Q3 Medicine

Journal of Oral and Maxillofacial Pathology Pub Date : 2024-04-01 Epub Date: 2024-07-11 DOI:10.4103/jomfp.jomfp_195_23

Priscila Marinho de Abreu, Marcella Sol, Patrícia Roccon Bianchi Molini, Camila Batista Daniel, Danielle Resende Camisasca, Sandra Ventorin von Zeidler

{"title":"Immunoexpression of CD44, p16 and VEGF in oral cancer.","authors":"Priscila Marinho de Abreu, Marcella Sol, Patrícia Roccon Bianchi Molini, Camila Batista Daniel, Danielle Resende Camisasca, Sandra Ventorin von Zeidler","doi":"10.4103/jomfp.jomfp_195_23","DOIUrl":null,"url":null,"abstract":"Objectives: The aim of the present study was to examine the immunoexpression of CD44, p16 and VEGF in oral squamous cell carcinoma (OSCC) and correlate them to clinicopathological parameters and survival outcomes in order to clarify their prognostic impact.Material and methods: A total of 68 individuals with OSCC recruited between 2011 and 2015 from two referral centres were enrolled in the study. The samples were placed on silanized glass slides and subjected to immunohistochemistry using anti-p16, anti-CD44 and anti-VEGF antibodies. The H Score was used for p16 and VEGF, while CD44 was scored according to the percentage of stained cells. Chi-square tests and Fisher's exact probability tests were used to compare clinicopathological characteristics according to the immunohistochemical expression, while overall survival and disease-free survival were estimated and compared using the Kaplan-Meier method and log-rank test, respectively. For all hypothesis tests, the level of significance was set at P ≤ 0.05.Results: No correlation was observed between the expression of tumour VEGF, p16 and CD44, and the clinicopathological characteristics analysed. Patients with high stromal VEGF expression had better disease-free survival than patients with low VEGF expression (P = 0.023).Conclusion: In summary, P16, CD44 and tumour VEGF did not prove to be good prognostic biomarkers. Stromal VEGF expression is suggested to be a good candidate prognostic biomarker, although additional studies are needed.","PeriodicalId":38846,"journal":{"name":"Journal of Oral and Maxillofacial Pathology","volume":"28 2","pages":"253-260"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329094/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral and Maxillofacial Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jomfp.jomfp_195_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The aim of the present study was to examine the immunoexpression of CD44, p16 and VEGF in oral squamous cell carcinoma (OSCC) and correlate them to clinicopathological parameters and survival outcomes in order to clarify their prognostic impact.

Material and methods: A total of 68 individuals with OSCC recruited between 2011 and 2015 from two referral centres were enrolled in the study. The samples were placed on silanized glass slides and subjected to immunohistochemistry using anti-p16, anti-CD44 and anti-VEGF antibodies. The H Score was used for p16 and VEGF, while CD44 was scored according to the percentage of stained cells. Chi-square tests and Fisher's exact probability tests were used to compare clinicopathological characteristics according to the immunohistochemical expression, while overall survival and disease-free survival were estimated and compared using the Kaplan-Meier method and log-rank test, respectively. For all hypothesis tests, the level of significance was set at P ≤ 0.05.

Results: No correlation was observed between the expression of tumour VEGF, p16 and CD44, and the clinicopathological characteristics analysed. Patients with high stromal VEGF expression had better disease-free survival than patients with low VEGF expression (P = 0.023).

Conclusion: In summary, P16, CD44 and tumour VEGF did not prove to be good prognostic biomarkers. Stromal VEGF expression is suggested to be a good candidate prognostic biomarker, although additional studies are needed.

查看原文本刊更多论文

口腔癌中 CD44、p16 和血管内皮生长因子的免疫表达。

研究目的本研究旨在检测口腔鳞状细胞癌（OSCC）中CD44、p16和VEGF的免疫表达，并将其与临床病理参数和生存结果相关联，以明确其对预后的影响：研究共纳入了 2011 年至 2015 年期间从两个转诊中心招募的 68 名 OSCC 患者。样本置于硅烷化玻璃载玻片上，使用抗 p16、抗 CD44 和抗 VEGF 抗体进行免疫组化。p16 和 VEGF 采用 H 评分，CD44 则根据染色细胞的百分比评分。根据免疫组化表达情况，采用卡普兰-梅耶法和对数秩检验比较临床病理特征，并使用卡普兰-梅耶法和对数秩检验估算和比较总生存期和无病生存期。所有假设检验的显著性水平均定为P≤0.05：结果：肿瘤血管内皮生长因子、p16和CD44的表达与所分析的临床病理特征之间没有相关性。基质 VEGF 高表达患者的无病生存率高于 VEGF 低表达患者（P = 0.023）：总之，P16、CD44 和肿瘤血管内皮生长因子并未被证明是良好的预后生物标志物。基质 VEGF 表达被认为是一个很好的候选预后生物标志物，尽管还需要更多的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oral and Maxillofacial Pathology Medicine-Otorhinolaryngology

CiteScore

1.40

自引率

0.00%

发文量

115

期刊介绍： The journal of Oral and Maxillofacial Pathology [ISSN:print-(0973-029X, online-1998-393X)] is a tri-annual journal published on behalf of “The Indian Association of Oral and Maxillofacial Pathologists” (IAOMP). The publication of JOMFP was started in the year 1993. The journal publishes papers on a wide spectrum of topics associated with the scope of Oral and Maxillofacial Pathology, also, ensuring scientific merit and quality. It is a comprehensive reading material for the professionals who want to upgrade their diagnostic skills in Oral Diseases; allows exposure to newer topics and methods of research in the Oral-facial Tissues and Pathology. New features allow an open minded thinking and approach to various pathologies. It also encourages authors to showcase quality work done by them and to compile relevant cases which are diagnostically challenging. The Journal takes pride in maintaining the quality of articles and photomicrographs.